HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Win 55212-2 (WIN 55,212)

Subscribe to New Research on Win 55212-2

a cannabinoid agonist; aminoalkylindole analog

Also Known As:

WIN 55,212; (2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate; 6H-Pyrrolo(3,2,1-ij)quinolin-6-one, 4,5-dihydro-2-methyl-4-(4-morpholinylmethyl)-1-(1-naphthalenylcarbonyl)-, (R)-; WIN 55.212-2; WIN 55212; WIN 55212-3; WIN-55212; WIN55212-2; Win-55212-2

Networked: 165 relevant articles (14 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Adler, Martin W: 8 articles (08/2009 - 06/2002)
2.	Luszczki, Jarogniew J: 7 articles (03/2015 - 04/2011)
3.	Geller, Ellen B: 7 articles (08/2009 - 06/2002)
4.	Florek-Luszczki, Magdalena: 5 articles (03/2015 - 12/2011)
5.	Rawls, Scott M: 4 articles (08/2007 - 06/2002)
6.	Wagner, Edward J: 3 articles (03/2015 - 01/2009)
7.	Wlaz, Aleksandra: 3 articles (03/2015 - 11/2013)
8.	Czuczwar, Stanislaw J: 3 articles (11/2013 - 04/2011)
9.	Choi, Myung-Gyu: 3 articles (01/2013 - 05/2010)
10.	Park, Jae Myung: 3 articles (01/2013 - 05/2010)

Related Diseases

1.	Hyperalgesia 11/23/2004 - "The aim of this study is to observe the effect of a high affinity cannabinoid, WIN 55,212-2, on tactile allodynia and thermal hyperalgesia in diabetic rats. " 12/01/2006 - "At the dose of 0.125 mg/kg iv, WIN 55,212-2 reversed the hyperalgesia produced by nerve injury. " 11/23/2004 - "The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats." 06/01/2004 - "injection of WIN 55,212-2 into the contralateral paw did not alter the heat-injury induced hyperalgesia, suggesting that the antihyperalgesia occurred through a peripheral mechanism. " 06/01/2004 - "The inactive enantiomer WIN 55,212-3 did not alter mechanical or heat hyperalgesia, suggesting the effects of WIN 55,212-2 were receptor-mediated. "
2.	Seizures (Seizure) 01/01/2015 - "Sub-acute treatment with WIN 55,212-2 (for 15days starting 24h after PILO injection) dramatically attenuated the severity, duration and frequency of spontaneous recurrent seizures. " 01/01/2012 - "Nissl and NeuN staining showed hippocampal injury was attenuated only when seizures were mild following low doses of WIN 55,212 (0.5, 1 mg/kg), consistent with the level of CB1 expression. " 01/01/2012 - "After KA administration, seizure scores and electroencephalography (EEG) recordings were inversely related to (R+)WIN 55,212 dosage whereby higher doses were associated with high seizures scores and synchronous epileptiform activity and low doses with low seizure scores and diminished spiking in the EEG. " 06/01/2006 - "WIN 55,212-2 produced dose-dependent anticonvulsant effects against both spontaneous recurrent epileptiform discharges (SRED) (EC50 = 0.85 microM) and SE (EC50 = 1.51 microM), with total suppression of seizure activity at 3 microM and of SE activity at 5 microM. " 01/01/2011 - "Changes in spontaneous local field potentials and seizure afterdischarges evoked by the electrical stimulation of the perforant path were recorded simultaneously in the hippocampus, entorhinal cortex, medial septal region, and amygdala after a preliminary intraventricular injection of WIN 55.212-2. It was found that WIN 55.212-2 blocked the stimulation-elicited seizures in 80% of tests. "
3.	Pain (Aches) 01/01/2009 - "The current study assessed the efficacy of the CB receptor agonist WIN 55,212-2 (WIN) in a rat model of neuropathic SCI pain. " 06/01/2009 - "Here, we characterized the anti-allodynic effects of WIN 55,212-2 (WIN) in a rat model of post-operative pain. " 06/01/2009 - "Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain." 04/15/2011 - "Intrathecal WIN 55,212-2 reduced bone tumor-related pain behavior mediated via spinal CB1 and CB2 receptors. " 12/01/2010 - "Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain."
4.	Hypothermia 12/01/1992 - "Stereoselectivity was demonstrated by the fact that (+)-WIN-55,212 (one isomer of a semirigid derivative possessing C2-H and C3-naphthoyl substituents) was moderately potent in all tests (ED50 values ranging from 0.25-23 mumol/kg), but (-)-WIN-55,212 was inactive up to 57 mumol/kg. Active aminoalkylindole compounds were generally least effective in the production of hypothermia. " 08/01/2007 - "In actual experiments, a cannabinoid agonist, WIN 55212-2 (2.5, 5, and 10 mg/kg, i.p.), caused significant hypothermia in male Sprague-Dawley rats (200-225 g). " 12/28/2006 - "WIN 55212-2 (1, 2.5, 5 and 10 mg/kg, i.m.) caused a significant hypothermia. " 05/01/2004 - "WIN 55212-2 (2.5 mg/kg im) produced a rapid hypothermia that peaked 45-90 min postinjection. " 02/01/2004 - "WIN 55212-2 (1-5 mg/kg, i.m.) produced dose-dependent hypothermia that peaked 45 to 90 min post-injection. "
5.	Hypersensitivity (Allergy) 03/01/2007 - "The current study evaluated the efficacy of the nonselective CB receptor agonist WIN 55,212-2 on tactile hypersensitivity in rats following a brief compression to the thoracic spinal cord. " 01/05/2009 - "Using the same paradigm, WIN 55,212-2 was then tested against the synaptically-induced nociceptive hypersensitivity in response to noxious thermal stimulation of the tail (hot water tail immersion). " 05/01/2007 - "When delivered to the contralateral side to injury, WIN 55,212-2 (1.4 or 2.8 microg microl(-1) hr(-1)) did not significantly affect nerve injury-associated hypersensitivity. " 05/01/2007 - "Compared with vehicle treatment, WIN 55,212-2 (1.4 microg microl(-1) hr(-1)) reduced hypersensitivity to stimuli applied to the injured limb at 2, 4 and 6 days after injury. " 05/01/2007 - "Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity."

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	CB2 Cannabinoid Receptor
3.	Cannabinoid Receptors (Cannabinoid Receptor)
4.	rimonabant
5.	Cannabinoids
6.	Tetrahydrocannabinol (THC)
7.	HU 211 (HU 210)
8.	Apolipoproteins E (ApoE)
9.	AM 251 (AM251)
10.	Paclitaxel (Taxol)

Related Therapies and Procedures

1.	Topical Administration
2.	Analgesia
3.	Induced Hypothermia
4.	Ligation
5.	Injections